Recurrent meningioma: Salvage therapy with long-acting somatostatin analogue

Marc C. Chamberlain, Michael Glantz, Camilo E. Fadul

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

BACKGROUND: Somatostatin receptors, especially the sst2A subtype, are present on most meningiomas. The addition of somatostatin inhibits meningioma growth in vitro in some studies. There have been anecdotal reports of octreotide inhibiting growth in meningiomas. OBJECTIVES: A prospective pilot trial of sustained-release somatostatin (Sandostatin LAR) in 16 patients with recurrent meningiomas was conducted with a primary study objective of progression-free survival at 6 months. METHODS: Sixteen patients (11 women, 5 men; median age 58) with recurrent meningioma were treated prospectively with long-acting somatostatin. Patients had progressed radiographically after prior therapy with surgery (14/16; complete resection in 5; subtotal in 7; biopsy only in 2), radiotherapy (13/16), and chemotherapy (12/16). All patients had confirmation of the presence of somatostatin receptors in their tumor using In-octreotide, a long-acting somatostatin agonist, SPECT scanning. RESULTS: Patients received 2 to 15 cycles (median 4.5) of somatostatin with minimal toxicity. Four partial responses, five stable disease, and seven progressive disease patterns were seen. Duration of response ranged from 2 to 20+ months (median 5.0 months). Median survival was 7.5 months (range 3 to 20+). The overall progression-free survival was 44% (seven patients) at 6 months. CONCLUSIONS: In this small trial of patients with recurrent meningiomas shown to overexpress somatostatin receptors by octreotide scintigraphy, long-acting somatostatin (Sandostatin LAR) was administered on a monthly schedule. Thirty-one percent of patients demonstrated a partial radiographic response and 44% achieved progression-free survival at 6 months. Toxicity was minimal, suggesting somatostatin analogues may offer a novel, relatively nontoxic alternative treatment for recurrent meningiomas.

Original languageEnglish (US)
Pages (from-to)969-973
Number of pages5
JournalNeurology
Volume69
Issue number10
DOIs
StatePublished - Sep 1 2007

Fingerprint

Salvage Therapy
Meningioma
Somatostatin
Octreotide
Disease-Free Survival
Somatostatin Receptors
Growth
Single-Photon Emission-Computed Tomography
Radionuclide Imaging
Appointments and Schedules
Radiotherapy
Biopsy
Drug Therapy
Survival
Therapeutics

All Science Journal Classification (ASJC) codes

  • Clinical Neurology

Cite this

Chamberlain, Marc C. ; Glantz, Michael ; Fadul, Camilo E. / Recurrent meningioma : Salvage therapy with long-acting somatostatin analogue. In: Neurology. 2007 ; Vol. 69, No. 10. pp. 969-973.
@article{c803ad2c2ef543448f9a8f38bfc08670,
title = "Recurrent meningioma: Salvage therapy with long-acting somatostatin analogue",
abstract = "BACKGROUND: Somatostatin receptors, especially the sst2A subtype, are present on most meningiomas. The addition of somatostatin inhibits meningioma growth in vitro in some studies. There have been anecdotal reports of octreotide inhibiting growth in meningiomas. OBJECTIVES: A prospective pilot trial of sustained-release somatostatin (Sandostatin LAR) in 16 patients with recurrent meningiomas was conducted with a primary study objective of progression-free survival at 6 months. METHODS: Sixteen patients (11 women, 5 men; median age 58) with recurrent meningioma were treated prospectively with long-acting somatostatin. Patients had progressed radiographically after prior therapy with surgery (14/16; complete resection in 5; subtotal in 7; biopsy only in 2), radiotherapy (13/16), and chemotherapy (12/16). All patients had confirmation of the presence of somatostatin receptors in their tumor using In-octreotide, a long-acting somatostatin agonist, SPECT scanning. RESULTS: Patients received 2 to 15 cycles (median 4.5) of somatostatin with minimal toxicity. Four partial responses, five stable disease, and seven progressive disease patterns were seen. Duration of response ranged from 2 to 20+ months (median 5.0 months). Median survival was 7.5 months (range 3 to 20+). The overall progression-free survival was 44{\%} (seven patients) at 6 months. CONCLUSIONS: In this small trial of patients with recurrent meningiomas shown to overexpress somatostatin receptors by octreotide scintigraphy, long-acting somatostatin (Sandostatin LAR) was administered on a monthly schedule. Thirty-one percent of patients demonstrated a partial radiographic response and 44{\%} achieved progression-free survival at 6 months. Toxicity was minimal, suggesting somatostatin analogues may offer a novel, relatively nontoxic alternative treatment for recurrent meningiomas.",
author = "Chamberlain, {Marc C.} and Michael Glantz and Fadul, {Camilo E.}",
year = "2007",
month = "9",
day = "1",
doi = "10.1212/01.wnl.0000271382.62776.b7",
language = "English (US)",
volume = "69",
pages = "969--973",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

Recurrent meningioma : Salvage therapy with long-acting somatostatin analogue. / Chamberlain, Marc C.; Glantz, Michael; Fadul, Camilo E.

In: Neurology, Vol. 69, No. 10, 01.09.2007, p. 969-973.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Recurrent meningioma

T2 - Salvage therapy with long-acting somatostatin analogue

AU - Chamberlain, Marc C.

AU - Glantz, Michael

AU - Fadul, Camilo E.

PY - 2007/9/1

Y1 - 2007/9/1

N2 - BACKGROUND: Somatostatin receptors, especially the sst2A subtype, are present on most meningiomas. The addition of somatostatin inhibits meningioma growth in vitro in some studies. There have been anecdotal reports of octreotide inhibiting growth in meningiomas. OBJECTIVES: A prospective pilot trial of sustained-release somatostatin (Sandostatin LAR) in 16 patients with recurrent meningiomas was conducted with a primary study objective of progression-free survival at 6 months. METHODS: Sixteen patients (11 women, 5 men; median age 58) with recurrent meningioma were treated prospectively with long-acting somatostatin. Patients had progressed radiographically after prior therapy with surgery (14/16; complete resection in 5; subtotal in 7; biopsy only in 2), radiotherapy (13/16), and chemotherapy (12/16). All patients had confirmation of the presence of somatostatin receptors in their tumor using In-octreotide, a long-acting somatostatin agonist, SPECT scanning. RESULTS: Patients received 2 to 15 cycles (median 4.5) of somatostatin with minimal toxicity. Four partial responses, five stable disease, and seven progressive disease patterns were seen. Duration of response ranged from 2 to 20+ months (median 5.0 months). Median survival was 7.5 months (range 3 to 20+). The overall progression-free survival was 44% (seven patients) at 6 months. CONCLUSIONS: In this small trial of patients with recurrent meningiomas shown to overexpress somatostatin receptors by octreotide scintigraphy, long-acting somatostatin (Sandostatin LAR) was administered on a monthly schedule. Thirty-one percent of patients demonstrated a partial radiographic response and 44% achieved progression-free survival at 6 months. Toxicity was minimal, suggesting somatostatin analogues may offer a novel, relatively nontoxic alternative treatment for recurrent meningiomas.

AB - BACKGROUND: Somatostatin receptors, especially the sst2A subtype, are present on most meningiomas. The addition of somatostatin inhibits meningioma growth in vitro in some studies. There have been anecdotal reports of octreotide inhibiting growth in meningiomas. OBJECTIVES: A prospective pilot trial of sustained-release somatostatin (Sandostatin LAR) in 16 patients with recurrent meningiomas was conducted with a primary study objective of progression-free survival at 6 months. METHODS: Sixteen patients (11 women, 5 men; median age 58) with recurrent meningioma were treated prospectively with long-acting somatostatin. Patients had progressed radiographically after prior therapy with surgery (14/16; complete resection in 5; subtotal in 7; biopsy only in 2), radiotherapy (13/16), and chemotherapy (12/16). All patients had confirmation of the presence of somatostatin receptors in their tumor using In-octreotide, a long-acting somatostatin agonist, SPECT scanning. RESULTS: Patients received 2 to 15 cycles (median 4.5) of somatostatin with minimal toxicity. Four partial responses, five stable disease, and seven progressive disease patterns were seen. Duration of response ranged from 2 to 20+ months (median 5.0 months). Median survival was 7.5 months (range 3 to 20+). The overall progression-free survival was 44% (seven patients) at 6 months. CONCLUSIONS: In this small trial of patients with recurrent meningiomas shown to overexpress somatostatin receptors by octreotide scintigraphy, long-acting somatostatin (Sandostatin LAR) was administered on a monthly schedule. Thirty-one percent of patients demonstrated a partial radiographic response and 44% achieved progression-free survival at 6 months. Toxicity was minimal, suggesting somatostatin analogues may offer a novel, relatively nontoxic alternative treatment for recurrent meningiomas.

UR - http://www.scopus.com/inward/record.url?scp=34548444537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548444537&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000271382.62776.b7

DO - 10.1212/01.wnl.0000271382.62776.b7

M3 - Article

C2 - 17785665

AN - SCOPUS:34548444537

VL - 69

SP - 969

EP - 973

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 10

ER -